MX2019014192A - Inhibidor de inmunosupresion asociado al cancer. - Google Patents

Inhibidor de inmunosupresion asociado al cancer.

Info

Publication number
MX2019014192A
MX2019014192A MX2019014192A MX2019014192A MX2019014192A MX 2019014192 A MX2019014192 A MX 2019014192A MX 2019014192 A MX2019014192 A MX 2019014192A MX 2019014192 A MX2019014192 A MX 2019014192A MX 2019014192 A MX2019014192 A MX 2019014192A
Authority
MX
Mexico
Prior art keywords
cancer
associated immunosuppression
inhibitor
immunosuppression inhibitor
glyco
Prior art date
Application number
MX2019014192A
Other languages
English (en)
Inventor
Mehdi Lahmar
Jean- Marc Barret
Jean- François Prost
Stéphane Degove
Houcine Bougherara
Emmanuel Donnadieu
Original Assignee
Gamamabs Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gamamabs Pharma filed Critical Gamamabs Pharma
Publication of MX2019014192A publication Critical patent/MX2019014192A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un compuesto portador de fragmento Fc modificado mediante glicoingeniería para su uso como un inhibidor de inmunosupresión en el tratamiento de una inmunosupresión asociada a cáncer. La invención se refiere además a una composición farmacéutica que comprende por lo menos este compuesto portador de fragmento Fc modificado mediante glicoingeniería.
MX2019014192A 2017-05-29 2018-05-29 Inhibidor de inmunosupresion asociado al cancer. MX2019014192A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305619 2017-05-29
PCT/EP2018/064081 WO2018219956A1 (en) 2017-05-29 2018-05-29 Cancer-associated immunosuppression inhibitor

Publications (1)

Publication Number Publication Date
MX2019014192A true MX2019014192A (es) 2021-04-12

Family

ID=59054051

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014192A MX2019014192A (es) 2017-05-29 2018-05-29 Inhibidor de inmunosupresion asociado al cancer.

Country Status (9)

Country Link
US (1) US20200148777A1 (es)
EP (1) EP3630826A1 (es)
JP (2) JP2020521780A (es)
KR (1) KR20200031571A (es)
CN (1) CN111108123A (es)
BR (1) BR112019025352A8 (es)
CA (1) CA3064333A1 (es)
MX (1) MX2019014192A (es)
WO (1) WO2018219956A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110023337B (zh) 2016-10-11 2024-01-05 艾吉纳斯公司 抗lag-3抗体及其使用方法
CN114716558B (zh) * 2022-04-12 2023-05-05 骏蓦(北京)生物科技有限公司 一种双特异性抗体及其治疗癌症的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1959018B1 (en) 2002-03-19 2011-05-11 Stichting Dienst Landbouwkundig Onderzoek Optimizing glycan processing in plants
AU2005259221B2 (en) 2004-07-01 2011-02-10 Innate Pharma Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
EP1888649A2 (en) * 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
PL2439273T3 (pl) 2005-05-09 2019-08-30 Ono Pharmaceutical Co., Ltd. Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami
JP2008541770A (ja) * 2005-06-03 2008-11-27 ジェネンテック・インコーポレーテッド 改変したフコシル化レベルを有する抗体の産生方法
NZ596322A (en) 2006-01-17 2013-02-22 Synthon Biopharmaceuticals Bv Compositions and methods for humanization and optimization of N-glycans in duckweed plants
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
CA2691357C (en) 2007-06-18 2014-09-23 N.V. Organon Antibodies to human programmed death receptor pd-1
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP4169951A1 (en) 2008-12-09 2023-04-26 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2459594A1 (en) 2009-07-31 2012-06-06 N.V. Organon Fully human antibodies to btla
AU2010286361A1 (en) 2009-08-31 2012-03-15 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
CN104961829B (zh) 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
FR2959994B1 (fr) 2010-05-12 2012-08-24 Lfb Biotechnologies Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii
PT2707391T (pt) * 2011-05-13 2018-02-06 Inserm Institut National De La Santa© Et De La Rech Ma©Dicale Anticorpos contra her3
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
FR2984750B1 (fr) * 2011-12-23 2014-01-10 Lfb Biotechnologies Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
MX2015014773A (es) * 2013-04-22 2016-03-04 Glycotope Gmbh Tratamientos anti-cancer con anticuerpos anti-egfr que tienen una fucosilacion baja.
CA2929386C (en) * 2013-11-07 2023-01-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Neuregulin allosteric anti-her3 antibody
FR3020063A1 (fr) * 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
CN106659774A (zh) * 2014-05-16 2017-05-10 贝勒研究院 用于治疗自身免疫和炎性病症的方法和组合物
EP3331569A1 (en) * 2015-08-07 2018-06-13 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
US9630575B2 (en) 2015-09-30 2017-04-25 GM Global Technology Operations LLC Panel assembly with noise attenuation system

Also Published As

Publication number Publication date
JP2023073965A (ja) 2023-05-26
WO2018219956A1 (en) 2018-12-06
RU2019137534A (ru) 2021-06-30
RU2019137534A3 (es) 2021-11-01
BR112019025352A8 (pt) 2023-05-02
CN111108123A (zh) 2020-05-05
EP3630826A1 (en) 2020-04-08
KR20200031571A (ko) 2020-03-24
BR112019025352A2 (pt) 2020-08-18
JP2020521780A (ja) 2020-07-27
US20200148777A1 (en) 2020-05-14
CA3064333A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
MX2022001165A (es) Composiciones terapeuticas, combinaciones y metodos de uso.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2021002455A (es) Metodos para tratar tumores de celulas epitelioides.
MX2018012016A (es) Compuestos biciclicos.
MX2019011496A (es) Composiciones de niraparib.
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
MX2018001990A (es) Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
MY189454A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
PH12016501702B1 (en) Pyrazole amide derivative
NZ725917A (en) Novel polymerase-i inhibitors, uses and methods for making them
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2022010755A (es) Inhibidores de quinasa y usos de los mismos.
MX2017007188A (es) Compuesto antimicotico.
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
PH12018500504A1 (en) Compounds useful for inhibiting ror-gamma-t
EP4306173A3 (en) Compositions and methods for treating cancers
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX2019014192A (es) Inhibidor de inmunosupresion asociado al cancer.
PH12017501601A1 (en) Use of isolated fractions of mastic gum for treating optic neuropathy
MA40027A (fr) Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique